A remarkable decrease in sBCMA level was previously observed in patients with good responses to BCMA-targeted immunotherapy, suggesting sBCMA as a suitable biomarker to assess response to MM therapy [11]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.